Phillip Md Et Al Frost Purchases 67,434 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 67,434 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were purchased at an average cost of $1.71 per share, with a total value of $115,312.14. Following the completion of the acquisition, the chief executive officer now directly owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. This represents a 0.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.56 per share, for a total transaction of $780,000.00.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.74 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company’s 50-day moving average price is $1.55 and its 200 day moving average price is $1.55. OPKO Health, Inc. has a 52 week low of $0.86 and a 52 week high of $1.84. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -9.16 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. As a group, research analysts forecast that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday.

Hedge Funds Weigh In On OPKO Health

Several hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP lifted its position in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Millennium Management LLC raised its stake in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Northern Trust Corp lifted its holdings in OPKO Health by 4.7% in the 4th quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock valued at $5,436,000 after purchasing an additional 164,847 shares in the last quarter. Lazard Asset Management LLC boosted its stake in shares of OPKO Health by 143.6% during the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after buying an additional 949,671 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.